Clinical trials: Hip Disease
Rheumatoid Arthritis, Osteoarthritis
A Single Centre Study to Assess the Long-term Performance of the Pinnacle™ Cup With a Ceramic-on-ceramic Bearing in Primary Total Hip Replacement
The purpose of this study is to monitor the performance of the Pinnacle™ Cup with a ceramic-on-ceramic bearing combination in the treatment of patients with hip joint disease requiring a total hip replacement.
- Conditions
- Rheumatoid Arthritis, Osteoarthritis, Post-traumatic Arthritis, Collagen Disorders
- Trial name
- NCT00872222
- Testing
- Pinnacle™ Acetabular System
- Where
- Czechia
- Volunteers
- 98 people
- Sponsor
- DePuy International
Arthroplasty, Replacement, Thromboembolism
Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery
An observational cohort study on safety and efficacy to generate additional data on the benefit/risk profile of the 150 mg dose of Pradaxa in patients with renal impairment
- Trial name
- NCT00847301
- Where
- 53 sites in Austria, France and 5 more
- Volunteers
- 472 people
- Sponsor
- Boehringer Ingelheim
Osteoarthritis, Hip, Avascular Necrosis of Hip
Avenir Complete Post-Market Clinical Follow-Up Study
The main objectives of this study are to confirm the long-term safety, performance and clinical benefits the Avenir Complete femoral stem and its instrumentation when used in primary total, hemi, and revision hip arthroplasty.
- Conditions
- Osteoarthritis, Hip, Avascular Necrosis of Hip, Avascular Necrosis of the Femoral Head, Post-traumatic; Arthrosis
- Trial name
- NCT04731077
- Testing
- Avenir Complete Femoral Stem
- Where
- 9 sites in United States, Denmark and 4 more
- Volunteers
- 275 people
- Sponsor
- Zimmer Biomet
Osteoarthritis
Gait Analysis of Anterior Versus Posterior Approach in Performance of Total Hip Arthroplasty
The primary objectives of the study is to compare gait kinematics and the return to normalization of gait in patients that have undergone a Total Hip Arthroplasty (THA) via the direct anterior approach versus the posterior…
- Trial name
- NCT00951951
- Testing
- Anterior Approach, Posterior Approach
- Where
- 4 sites in United States
- Volunteers
- 64 people
- Sponsor
- Medacta USA
Osteoarthritis, Avascular Necrosis
AL-2 MP-1 (Polyimide) Acetabular Liner
M.M.A.TECH Ltd. product is an Acetabular Liner Family produced of an advanced polyimide - MP-1™. M.M.A.TECH Ltd. produces the Liners according to EN ISO 13485:2012 approved manufacturing process and supplies them to the customer.
- Conditions
- Osteoarthritis, Avascular Necrosis, Rheumatoid Arthritis, Congenital Dysplasia of the Hip
- Trial name
- NCT02503891
- Testing
- MP-1 Polymer on Ceramic Articulation system
- Where
- Israel
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- M.M.A Tech Ltd.
Hip Arthropathy, Hip Osteoarthritis
Post Market Clinical Follow-up of EUROSCUP Fixe Acetabular Cup
EUROSCUP Fixe is intended for use in primary and revision total hip replacement surgery. Hip replacement is intended to provide increased patient mobility and reduce pain by replacing the damages hip joint articulation in…
- Conditions
- Hip Arthropathy, Hip Osteoarthritis, Hip Necrosis, Hip Fractures
- Trial name
- NCT05142462
- Testing
- Hip arthroplasty
- Where
- 4 sites in France
- Volunteers
- 120 people
- Sponsor
- EUROS
Osteoarthritis, Hip, Rheumatoid Arthritis
Avenir Müller Hip Stem Post Market Surveillance Study
This study is a Post Market Clinical Follow up study to fulfil the post market surveillance obligations according to Medical Device Directive and European Medical Device Vigilance System (MEDDEV) 2.12-2.
- Conditions
- Osteoarthritis, Hip, Rheumatoid Arthritis, Fracture of Hip, Dislocated Hip
- Trial name
- NCT04079127
- Testing
- Patients who met the inclusion/exclusion criteria to receive the Avenir Müller stem.
- Volunteers
- 150 people
- Sponsor
- Zimmer Biomet
Thromboembolism
Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events
This study is being carried out to study the efficacy and safety of treatment with melagatran injection followed by ximelagatran tablets in preventing blood clots, compared with enoxaparin for a period of 5-6 weeks.
- Trial name
- EXTEND (NCT00206089)
- Testing
- EXANTA
- Where
- 125 sites in Austria, Belgium and 14 more
- Volunteers
- 3,300 people
- Sponsor
- AstraZeneca
Venous Thromboembolism
Dose Ranging Study in Elective Total Hip Replacement Surgery
The primary objective is to: demonstrate the efficacy of SR123781A in the prevention of venous thromboembolism (VTE) by the demonstration of a dose-response in patients undergoing total hip replacement surgery.
- Trial name
- DRIVE (NCT00338897)
- Testing
- SR123781A
- Where
- 14 sites in Argentina, Bulgaria and 12 more
- Volunteers
- 1,090 people
- Sponsor
- Sanofi
Rheumatoid Arthritis, Osteoarthritis
G7 BiSpherical Acetabular Shell PMCF Study
The primary objective of this study is to obtain implant survivorship and clinical outcomes data for the commercially available G7 BiSpherical Acetabular Shell.
- Conditions
- Rheumatoid Arthritis, Osteoarthritis, Noninflammatory Degenerative Joint Disease, Avascular Necrosis
- Trial name
- NCT03266874
- Where
- 5 sites in France, Germany and 2 more
- Volunteers
- 160 people
- Sponsor
- Zimmer Biomet
Venous Thromboembolism
Dose-confirmatory Bridging Study in Total Hip Replacement
The objective of this dose-confirmatory bridging study is to investigate the safety and efficacy of rivaroxaban 5 to 10 mg once-daily (od) dosing in the prevention of venous thromboembolism (VTE) in Japanese patients undergoing…
- Trial name
- NCT01205932
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 41 sites in Japan
- Volunteers
- 402 people
- Sponsor
- Bayer
Venous Thromboembolism
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery
The purpose of this study is to examine the superiority of YM150 to the placebo and to evaluate the dose-dependent response of YM150 in patients undergoing elective total hip replacement surgery.
- Trial name
- NCT00913120
- Testing
- YM150, Enoxaparin
- Where
- 16 sites in Japan, South Korea and 2 more
- Volunteers
- 610 people
- Sponsor
- Astellas Pharma Inc
Non-inflammatory Degenerative Joint Disease, Osteoarthritis
A Clinical Investigation of the M2a- 38™ Hip System
The purpose of this prospective clinical data collection is to document the performance and clinical outcomes of the M2a- 38™ Hip System
- Conditions
- Non-inflammatory Degenerative Joint Disease, Osteoarthritis, Avascular Necrosis
- Trial name
- NCT00698503
- Volunteers
- 190 people
- Sponsor
- Biomet Orthopedics, LLC
Hip Osteoarthritis, Acute Traumatic Fracture of the Femoral Head or Neck
Z1 Hip System: Post-Market Clinical Follow Up Study
The objectives of this study are to confirm the early to mid- term safety, performance, and clinical benefits of the Z1 Femoral Hip System in hemi- and primary total hip arthroplasty.
- Conditions
- Hip Osteoarthritis, Acute Traumatic Fracture of the Femoral Head or Neck, Avascular Necrosis of the Femoral Head
- Trial name
- NCT07104279
- Testing
- Z1 Femoral Hip System
- Where
- 5 sites in United States
- Volunteers
- 300 people
- Sponsor
- Zimmer Biomet
Healthy, Osteopenia
Clinical Study to Predict the Risk of Bone Fractures With the POROUS Ultrasound Device
Osteoporosis is a widespread medical condition among older people. It causes the bones to weaken and become more likely to break.
- Conditions
- Healthy, Osteopenia, Osteoporosis
- Trial name
- POROUS-preFX (NCT06567054)
- Testing
- Measurements with the POROUS R3C ultrasound device at the midshaft tibia, DXA measurement of the hip and lumbar spine, DXA-based Vertebral Fracture Assessment (VFA)
- Where
- 6 sites in Austria, Germany and 1 more
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- POROUS GmbH
Rheumatoid Arthritis, Osteoarthritis
A Study to Assess the Long-term Performance of SmartSet® HV and SmartSet® GHV Bone Cements in Primary Total Hip Replacement
The purpose of this study is to monitor the performance of artificial hip joints implanted with two different bone cements, SmartSet® HV and SmartSet® GHV, in the treatment of patients with hip joint disease requiring a total hip…
- Conditions
- Rheumatoid Arthritis, Osteoarthritis, Post-traumatic Arthritis, Collagen Disorders
- Trial name
- NCT00872066
- Testing
- SmartSet® HV bone cement, SmartSet® GHV bone cement
- Where
- Slovakia
- Volunteers
- 243 people
- Sponsor
- DePuy International
Venous Thromboembolism
Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
Patients undergoing surgery, especially hip and knee surgery, are at high risk for VTE. The administration of drugs for thromboprophylaxis, such as heparins, significantly lowers that risk, but heparins have to be applied by…
- Trial name
- ODIXa-HIP2 (NCT00398905)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin
- Where
- 61 sites in Austria, Belgium and 11 more
- Volunteers
- 726 people
- Sponsor
- Bayer
Thromboembolism, Arthroplasty, Replacement, Hip
Study to Evaluate the Safety and Efficacy of Pradaxar for the Prevention of Venous Thromboembolism in the Mexican Population Undergoing Elective Total Hip or Knee Replacement Surgery
Open, prospective, uncontrolled, observational cohort study.
- Trial name
- NCT00967447
- Where
- 28 sites in Mexico
- Volunteers
- 2 people
- Sponsor
- Boehringer Ingelheim
Degenerative Joint Disease, Osteoarthritis, Hip
Safety and Effectiveness of the HIT Reverse HRS
The purpose of this study is to determine if the use of the HIT Reverse Hip Replacement System is safe and effective in patients undergoing total hip replacement.
- Conditions
- Degenerative Joint Disease, Osteoarthritis, Hip, Avascular Necrosis of Hip, Traumatic Arthropathy-Hip
- Trial name
- NCT05357378
- Testing
- Hip Innovation Technology Reverse Hip Replacement System, Already-marketed semi-constrained uncemented hip systems using a metal-on-XLPE or ceramic-on-XLPE bearing combination.
- Where
- 6 sites in United States
- Volunteers
- 288 people
- Sponsor
- Hip Innovation Technology
Osteoarthritis, Hip
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
The primary objective of this study was to demonstrate any changes in assessments of pain for participants receiving Synvisc-One compared to control.
- Trial name
- NCT01618708
- Testing
- Synvisc-One (hylan G-F 20)
- Where
- 48 sites in United States, Canada
- Volunteers
- 357 people
- Sponsor
- Genzyme, a Sanofi Company